Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma

Biochemical Pharmacology

Volumn 79, Issue 4, 2010, Pages 535-541

  Zuco, Valentina ^a   Supino, Rosanna ^a   Favini, Enrica ^a   Tortoreto, Monica ^a   Cincinelli, Raffaella ^a   Croce, Anna Cleta ^b   Bucci, Federica ^c   Pisano, Claudio ^c   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

Camptothecin; Drug resistance; ST1968; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GIMATECAN; GLYCOPROTEIN P; NAMITECAN; ST 1968; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG RETENTION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71349085482     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.012     Document Type: Article

References (20)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Rev 6 (2006) 789-802
2. Thomas C.J., Rahier N.J., and Hecht S.M. Camptothecin: current perspectives. Bioorg Med Chem 12 (2004) 1585-1604
3. Teicher B.A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 75 (2008) 1262-1271
4. Beretta G.L., and Zunino F. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem Pharmacol 74 (2007) 1437-1444
5. Dallavalle S., Delsoldato T., Ferrari A., Merlini L., Penco S., Carenini N., et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem 43 (2000) 3963-3969
6. De Cesare M., Pratesi G., Perego P., Carenini N., Tinelli S., Merli L., et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61 (2001) 7189-7195
7. Dallavalle S., Ferrari A., Biasotti B., Merlini L., Penco S., Gallo G., et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 44 (2001) 3264-3274
8. De Cesare M., Beretta G.L., Tinelli S., Benedetti V., Pratesi G., Penco S., et al. Preclinical efficacy of ST1976, a novel camptothecin analog of 7-oxyiminomethyl series. Biochem Pharmacol 73 (2007) 656-664
9. Pisano C., De Cesare M., Beretta G.L., Zuco V., Pratesi G., Penco S., et al. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther 7 (2008) 2051-2059
10. Pisano C., Zuco V., De Cesare M., Benedetti V., Vesci L., Foderà R., et al. Intracellular accumulation and DNA damage persistence as determinant of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. Eur J Cancer 44 (2008) 1332-1340
11. Zuco V., Zanchi C., Cassinelli G., Lanzi C., Supino R., Pisano C., et al. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atipica retinoid. Cell Death Differ 11 (2004) 280-289
12. Workman P., Twentyman P., Balkwill F., Balmain A., Chaplin D., Double J., et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77 (1998) 1-10
13. Polizzi D., Pratesi G., Tortoreto M., Supino R., Riva A., and Bombardelli E. A novel taxane with improbe tolerability and therapeutic activity in a panel of human tumor xenograft. Cancer Res 59 (1999) 1036-1040
14. Ouar Z., Bens M., Vignes C., Paulais M., Pringel C., Fleury J., et al. Inhibitors of vacuolar H + -ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 370 (2003) 185-193
15. Petrangolini G., Supino R., Pratesi G., Dal Bo L., Tortoreto M., Croce A.C., et al. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther 318 (2006) 939-1036
16. 2 is a consequence of lisosoma rupture. Biochem J 356 (2001) 549-555
17. Croce A.C., Bottiroli G., Supino R., Favini E., Zuco V., and Zunino F. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol 67 (2004) 1035-1045
18. Beretta G.L., Perego P., and Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 13 (2006) 3291-3305
19. Rasheed Z.A., and Rubin E.H. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22 (2003) 7296-7304
20. Marchetti S., Oostendorp R.L., Pluim D., van Eijndhoven M., van Tellingen O., Schinkel A.H., et al. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Mol Cancer Ther 6 (2007) 3307-3313